Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Monday, MarketBeat.com reports. The firm presently has a $328.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $280.00. JPMorgan Chase & Co.‘s target price indicates a potential upside of 16.74% from the stock’s current price.

Several other research analysts also recently commented on the company. Royal Bank of Canada increased their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

Alnylam Pharmaceuticals Stock Down 3.4 %

Shares of NASDAQ ALNY opened at $280.96 on Monday. The firm has a market cap of $36.37 billion, a price-to-earnings ratio of -129.47 and a beta of 0.39. The company’s 50-day simple moving average is $258.62 and its 200-day simple moving average is $260.26. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP increased its position in shares of Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 38 shares during the period. Investment Management Corp of Ontario grew its stake in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after purchasing an additional 40 shares in the last quarter. Nixon Peabody Trust Co. increased its holdings in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 43 shares during the period. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 44 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 47 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.